[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-338225-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-338225-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","aberrant-positivity-for-bcor-immunohistochemistry-in-merkel-cell-carcinoma-a-potential-diagnostic-pitfall","Aberrant positivity for BCOR immunohistochemistry in Merkel cell carcinoma - a potential diagnostic pitfall","","Merkel cell carcinoma (MCC) is a rare, aggressive primary cutaneous neuroendocrine carcinoma with challenging diagnosis due to varied clinical features and broad histological differentials. Histology overlaps with basal cell carcinoma, melanoma, hematologic malignancies, round cell sarcoma, and metastatic small cell carcinoma. The study reports strong aberrant BCOR immunoreactivity in MCC, including nuclear and/or cytoplasmic staining, and evaluates its frequency and diagnostic impact across MCC, SCLC, and BCOR-altered neoplasms.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/aberrant-positivity-for-bcor-immunohistochemistry-in-merkel-cell-carcinoma-a-potential-diagnostic-pitfall/338225/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/aberrant-positivity-for-bcor-immunohistochemistry-in-merkel-cell-carcinoma-a-potential-diagnostic-pitfall/338225.png","ImageObject",300,407,{"name":42,"@type":43},"Riley","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-07","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is Merkel cell carcinoma (MCC) difficult to diagnose histologically?","Question",{"text":63,"@type":64},"MCC shows a small round blue-cell pattern and can overlap with several entities, including basal cell carcinoma, melanoma, hematologic malignancies, round cell sarcoma, and metastatic small cell carcinoma.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What diagnostic pitfall does BCOR immunohistochemistry introduce in MCC?",{"text":68,"@type":64},"The study finds strong aberrant BCOR positivity in MCC, even when cases are clinically suspected to be round cell sarcoma, creating a risk of misclassification.",{"name":70,"@type":61,"acceptedAnswer":71},"How common is BCOR positivity across the analyzed MCC and SCLC cohorts?",{"text":72,"@type":64},"In a larger retrospective MCC cohort, aberrant weak to strong BCOR positivity was observed in up to 90% of cases. In the analyzed SCLC cohort, all cases showed diffuse moderate to strong BCOR positivity.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},338225,1790439959,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","Vetter et al. Diagnostic Pathology (2024) 19:130 [https://doi.org/10.1186/s13000-024-01552-8](https://doi.org/10.1186/s13000-024-01552-8)  \nDiagnostic Pathology  \nRESEARCH Open Access  \nAberrant positivity for BCOR immunohistochemistry in merkel cell carcinoma-a potential diagnostic pitfall  \nViola Katharina Vetter 1, Martina Haberecker 1, Florian Alexander Huber2 and Chantal Pauli 1,3*  \nAbstract  \nBackrgound Merkel cell carcinoma (MCC) is a rare, aggressive primary cutaneous neuroendocrine carcinoma, frequently associated with clonal Merkel cell polyomavirus integration. MCC can pose significant diagnostic challenges due to its diverse clinical presentation and its broad histological differential diagnosis. Histologically, MCC presents as a small-round-blue cell neoplasm, where the differential diagnosis includes basal cell carcinoma, melanoma, hematologic malignancies, round cell sarcoma and metastatic small cell carcinoma of any site. We here report strong aberrant immunoreactivity for BCOR in MCC, a marker commonly used to identify round cell sarcomasand other neoplasms with BCOR alterations.  \nMethods Based on strong BCOR expression in three index cases of MCC, clinically mistaken as sarcoma, a retrospective analysis of three patient cohorts, comprising 31 MCC, 19 small cell lung carcinoma (SCLC) and 5 cases of neoplasms with molecularly confirmed BCOR alteration was conducted. Immunohistochemical staining intensity and localization for BCOR was semi-quantitatively analyzed.  \nResults Three cases, clinically and radiologically mimicking a sarcoma were analyzed in our soft tissue and bone pathology service. Histologically, the cases showed sheets of a small round blue cell neoplasm. A broad panel of immunohistochemistry was used for lineage classification. Positivity for synaptophysin, CK20 and Merkel cell polyoma virus large T-antigen lead to the diagnosis of a MCC. Interestingly, all cases showed strong positive nuclear staining for BCOR, which was included for the initial work-up with the clinical differential of a round cell sarcoma. We analyzed a larger retrospective MCC cohort and found aberrant weak to strong BCOR positivity (nuclear and/or cytoplasmic) in up to 90% of the cases. As a positive control, we compared the expression to a small group of BCOR-altered neoplasms. Furthermore, we investigated a cohort of SCLC as another neuroendocrine neoplasm and found in all cases a diffuse moderate to strong BCOR positivity.  \nConclusions This study demonstrates that neuroendocrine neoplasms, such as MCC and SCLC can express strong aberrant BCOR. This might represent a diagnostic challenge or pitfall, in particular when MCC is clinically mistaken as a soft tissue or a bone sarcoma.  \nKeywords Merkel cell carcinoma, BCOR, Immunohistochemistry, Neuroendocrine carcinoma, SCLC, Sarcoma  \n*Correspondence: Chantal Pauli  \nchantal.pauli@usz.ch  \n1Department of Pathology and Molecular Pathology, University Hospital Zurich, Schmelzbergstrasse 12, Zurich 8006, Switzerland  \n2Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Zurich, Switzerland  \n3Medical Faculty, University of Zurich, Zurich, Switzerland  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intende","cbCaivFEzImCjlvl","https://ap.wps.com/l/cbCaivFEzImCjlvl","pdf",3704925,"English","# Abstract\n# Methods\n# Results\n# Conclusions\n# Keywords\n# Introduction","[{\"question\":\"Why is Merkel cell carcinoma (MCC) difficult to diagnose histologically?\",\"answer\":\"MCC shows a small round blue-cell pattern and can overlap with several entities, including basal cell carcinoma, melanoma, hematologic malignancies, round cell sarcoma, and metastatic small cell carcinoma.\"},{\"question\":\"What diagnostic pitfall does BCOR immunohistochemistry introduce in MCC?\",\"answer\":\"The study finds strong aberrant BCOR positivity in MCC, even when cases are clinically suspected to be round cell sarcoma, creating a risk of misclassification.\"},{\"question\":\"How common is BCOR positivity across the analyzed MCC and SCLC cohorts?\",\"answer\":\"In a larger retrospective MCC cohort, aberrant weak to strong BCOR positivity was observed in up to 90% of cases. In the analyzed SCLC cohort, all cases showed diffuse moderate to strong BCOR positivity.\"}]","Aberrant positivity for BCOR immunohistochemistry in Merkel cell carcinoma - a potential diagnostic pitfall | PDF",1790022617,25,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f6cd67a045208d3c1b196c4a6f906ab8.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9412edd323273397327b64109761a7b4.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7fa6eaa925ce8a87ef6866a9b25f6e51.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/24ed6e405050cc44dc540f106e7ad702.webp",980,1306]